arrow
K

Karthik Ramasamy

oxford translational myeloma centre
H指数:30
被引数:3,608

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma

NGS-based靶向测序指导多发性骨髓瘤的风险适应性及分子靶向治疗决策

2025-08-260
OAAI
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events

Belantamab Mafodotin相关眼部事件的临床管理实用指南

2025-07-280
OAAI
Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper

单克隆免疫球蛋白血症肾病患者诊断与管理:英国血液学学会良好实践指南

2025-01-071
OAAI
Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

开发一个空间多组学平台,用于整合基因组、转录组及蛋白质组特征,以支持多发性骨髓瘤的转化研究

BLOOD
IF23.1
2024-11-051
PRE
Secure: A Prospective Long-Term Observational Study in Patients with Monoclonal Gammopathy of Undetermined Significance

安全:一项前瞻性长期观察研究,研究对象为意义未明的单克隆丙种球蛋白病患者

BLOOD
IF23.1
2024-11-050
PRE
A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

一种基于分割的纯度感知新方法可准确检测骨髓瘤靶向测序数据中的总拷贝数及其亚克隆分数

BLOOD
IF23.1
2024-11-050
PRE
Increased Rates of MRD Conversion from Positive ( plus ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

与化疗巩固治疗相比,新诊断多发性骨髓瘤患者在自体干细胞移植(ASCT)后MRD(微小残留病)从阳性转为阴性的比率增加,是改善无进展生存期的预后指标:英国MRA Cardamon试验中的动态MRD评估

BLOOD
IF23.1
2024-11-050
PRE
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma
2024-01-250
OAAI
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
2023-09-1433
PRE